Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2

Mostrar otras versiones (1)

There is currently a lack of biological tools to study the replication cycle and pathogenesis of SARS-CoV-2, the etiological agent of COVID-19. Repurposing the existing tools, including antibodies of SARS-CoV, is an effective way to accelerate the development of therapeutics for COVID-19. Here, we e...

Descripción completa

Detalles Bibliográficos
Autores principales: Bates, Timothy A., Weinstein, Jules B., Farley, Scotland E., Leier, Hans C., Messer, William B., Tafesse, Fikadu G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402058/
https://www.ncbi.nlm.nih.gov/pubmed/32766589
http://dx.doi.org/10.1101/2020.07.30.229377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402058/
https://www.ncbi.nlm.nih.gov/pubmed/32766589
http://dx.doi.org/10.1101/2020.07.30.229377

Ejemplares similares